PURA - Puration Announces $3 Million Annual Revenue Business Plan Update Presentation Scheduled Tuesday May 6th
June 01 2017 - 8:48AM
InvestorsHub NewsWire
Dallas, TX – June 1, 2017
- InvestorsHub NewsWire – Puration, Inc. (USOTC:
PURA) today announced an online, on-demand presentation to be
available on the Company’s website next Tuesday, June
6th. The purpose of the presentation is to present
updates to the Company’s business plan and plan to build to $3
million in annual revenue. The updates stem from the
impending acquisition of the controlling interest in PURA by
American Cannabis Innovations Conglomerated
(“ACI”). The acquisition is anticipated to be
finalized prior to the update presentation. The presentation
will include updates to the Company’s ongoing contract with Alkame
Holdings, Inc. (USOTC: ALKM). The presentation will also
include updates to PURA’s ongoing business relationship with North
American Cannabis Holdings, Inc. (USOTC: USMJ). Furthermore,
the presentation will include new developments with the Company’s ongoing work with NCM Biotech.
PURA Market Capitalization Improvements Summary – No
Reverse or Forward Split
The common stock of PURA will remain traded on the OTC Markets with
no forward or reverse split taking place in conjunction with the
ACI transaction. ACI expects the potential for market
capitalizations of PURA to improve by transitioning the Company
toward better investment structures, with better terms, that are
altogether better suited to the current and more mature stage of
development. For instance, PURA recently announced a
substantial convertible debt elimination in
conjunction with the pending ACI transaction in addition to a
$10 million funding
commitment.
ACI Business Plan
ACI is a private equity backed rollup founded to combine a variety
of leading young cannabis companies with complimentary offerings
and synergistic operations. PURA and USMJ are the first of five
acquisitions in the cannabis sector ACI has planned for the near
future. ACI is seeking to acquire early stage, undervalued
businesses with intellectual properties validated by market tests,
and commercial or consumer sales. ACI expects to improve the
operating efficiency of acquired assets by streaming redundant
functions and leveraging complimentary functions.
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Apr 2023 to Apr 2024
